Simon Cancer Center

Indiana University

Indianapolis, IN

Sorting 8 by

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
  • Bispecific Antibody
  • BCMA
  • Phase 1

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Multiple Myeloma Biorepository

Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Myeloma Registry

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3

Accepting patients

LINKER-MM1

First in Human (FIH) Study of Linvoseltamab (REGN5458) in Patients With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2
  • Has results

Not currently accepting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
  • Bispecific Antibody
  • BCMA
  • Phase 3
1 hidden based on your filters. Show All